CI
UTHR icon

CX Institutional’s United Therapeutics UTHR Stock Holding History

CX Institutional’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21K Hold
39
– – ﹤0.01% 1172
2026
Q1 		$23K Buy
+39
New +$19.4K ﹤0.01% 1103

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

CX Institutional's UTHR Position: Q2 2026 in Review

CX Institutional held its United Therapeutics (UTHR) position steady in Q2 2026 at 39 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #1172.

CX Institutional first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. The position peaked at $23K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • CX Institutional held 39 shares of United Therapeutics worth $21K as of Q2 2026.
  • CX Institutional left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of CX Institutional's portfolio in Q2 2026, its #1172 holding.
  • CX Institutional first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • CX Institutional's United Therapeutics position peaked at $23K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.